Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation

Atsushi Nonami, Katsuto Takenaka, Kenjiro Kamezaki, Toshihiro Miyamoto, Naoki Harada, Koji Nagafuji, Takanori Teshima, Mine Harada

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Primary cardiac lymphoma (PCL) is defined as lymphoma involving only the heart and/or pericardium, or with an intrapericardial location of the main tumor mass. It is an extremely rare type of lymphoma and has a poor prognosis because of diagnostic delay and the disease site. PCL is histologically characterized by a mostly diffuse large B-cell lymphoma. The median survival time has been reported to be 7 months. We present the case of a 55-year-old woman who presented with chest oppression and dyspnea on effort. Following a close examination, PCL with a high International Prognostic Index was diagnosed. She received 6 courses of R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and achieved complete remission. The patient then underwent a consolidation therapy consisting of high-dose chemotherapy including rituximab, followed by autologous peripheral blood stem cell transplantation. There were no complications, such as pulmonary embolism, fatal arrhythmia, or acute heart failure, throughout chemotherapy. Our experience indicates that this therapy is safe and effective and can improve the outcome of high-risk PCL.

Original languageEnglish
Pages (from-to)264-266
Number of pages3
JournalInternational Journal of Hematology
Volume85
Issue number3
DOIs
Publication statusPublished - Apr 1 2007

Fingerprint

Peripheral Blood Stem Cell Transplantation
Lymphoma
Drug Therapy
Therapeutics
Lymphoma, Large B-Cell, Diffuse
Pericardium
Vincristine
Prednisolone
Pulmonary Embolism
Dyspnea
Doxorubicin
Cyclophosphamide
Rituximab
Cardiac Arrhythmias
Thorax
Heart Failure
Survival
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation. / Nonami, Atsushi; Takenaka, Katsuto; Kamezaki, Kenjiro; Miyamoto, Toshihiro; Harada, Naoki; Nagafuji, Koji; Teshima, Takanori; Harada, Mine.

In: International Journal of Hematology, Vol. 85, No. 3, 01.04.2007, p. 264-266.

Research output: Contribution to journalArticle

@article{143cf51f10e14b138db977dcfc84e222,
title = "Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation",
abstract = "Primary cardiac lymphoma (PCL) is defined as lymphoma involving only the heart and/or pericardium, or with an intrapericardial location of the main tumor mass. It is an extremely rare type of lymphoma and has a poor prognosis because of diagnostic delay and the disease site. PCL is histologically characterized by a mostly diffuse large B-cell lymphoma. The median survival time has been reported to be 7 months. We present the case of a 55-year-old woman who presented with chest oppression and dyspnea on effort. Following a close examination, PCL with a high International Prognostic Index was diagnosed. She received 6 courses of R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and achieved complete remission. The patient then underwent a consolidation therapy consisting of high-dose chemotherapy including rituximab, followed by autologous peripheral blood stem cell transplantation. There were no complications, such as pulmonary embolism, fatal arrhythmia, or acute heart failure, throughout chemotherapy. Our experience indicates that this therapy is safe and effective and can improve the outcome of high-risk PCL.",
author = "Atsushi Nonami and Katsuto Takenaka and Kenjiro Kamezaki and Toshihiro Miyamoto and Naoki Harada and Koji Nagafuji and Takanori Teshima and Mine Harada",
year = "2007",
month = "4",
day = "1",
doi = "10.1532/IJH97.06197",
language = "English",
volume = "85",
pages = "264--266",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation

AU - Nonami, Atsushi

AU - Takenaka, Katsuto

AU - Kamezaki, Kenjiro

AU - Miyamoto, Toshihiro

AU - Harada, Naoki

AU - Nagafuji, Koji

AU - Teshima, Takanori

AU - Harada, Mine

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Primary cardiac lymphoma (PCL) is defined as lymphoma involving only the heart and/or pericardium, or with an intrapericardial location of the main tumor mass. It is an extremely rare type of lymphoma and has a poor prognosis because of diagnostic delay and the disease site. PCL is histologically characterized by a mostly diffuse large B-cell lymphoma. The median survival time has been reported to be 7 months. We present the case of a 55-year-old woman who presented with chest oppression and dyspnea on effort. Following a close examination, PCL with a high International Prognostic Index was diagnosed. She received 6 courses of R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and achieved complete remission. The patient then underwent a consolidation therapy consisting of high-dose chemotherapy including rituximab, followed by autologous peripheral blood stem cell transplantation. There were no complications, such as pulmonary embolism, fatal arrhythmia, or acute heart failure, throughout chemotherapy. Our experience indicates that this therapy is safe and effective and can improve the outcome of high-risk PCL.

AB - Primary cardiac lymphoma (PCL) is defined as lymphoma involving only the heart and/or pericardium, or with an intrapericardial location of the main tumor mass. It is an extremely rare type of lymphoma and has a poor prognosis because of diagnostic delay and the disease site. PCL is histologically characterized by a mostly diffuse large B-cell lymphoma. The median survival time has been reported to be 7 months. We present the case of a 55-year-old woman who presented with chest oppression and dyspnea on effort. Following a close examination, PCL with a high International Prognostic Index was diagnosed. She received 6 courses of R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and achieved complete remission. The patient then underwent a consolidation therapy consisting of high-dose chemotherapy including rituximab, followed by autologous peripheral blood stem cell transplantation. There were no complications, such as pulmonary embolism, fatal arrhythmia, or acute heart failure, throughout chemotherapy. Our experience indicates that this therapy is safe and effective and can improve the outcome of high-risk PCL.

UR - http://www.scopus.com/inward/record.url?scp=34247574008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247574008&partnerID=8YFLogxK

U2 - 10.1532/IJH97.06197

DO - 10.1532/IJH97.06197

M3 - Article

VL - 85

SP - 264

EP - 266

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -